Temozolomide is a pill- or infusion-based cancer drug used against glioblastoma and related tumors; current news centers on NHS funding decisions expanding its life-extending use.
Three BBC investigations have revealed repeated failures in UK cancer care: a final review has found harm from misdiagnosis and inappropriate treatment by former Belfast neurologist Michael Watt; Coventry patients were prescribed temozolomide for years with little evidence of benefit; and England is missing cancer-treatment targets, with only 69.9% starting within 62 days. Officials and families are demanding answers.